Trial reportInfluenza and other respiratory viruses2013
Low-dose oral interferon alpha as prophylaxis against viral respiratory illness: a double-blind, parallel controlled trial during an influenza pandemic year.
Trial report in Influenza and other respiratory viruses, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 40 citations in OpenAlex.
- Randomized, double-blind, placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infections.BMC infectious diseases · 2017Trial
- Low-dose oral interferon alpha as prophylaxis against viral respiratory illness: a double-blind, parallel controlled trial during an influenza pandemic year.Influenza and other respiratory viruses · 2013Trial
- Interferon as an immunoadjuvant to enhance antibodies following influenza B infection and vaccination in ferrets.NPJ vaccines · 2024Article
- An intranasal nanoparticle STING agonist protects against respiratory viruses in animal models.Nature communications · 2024Article
- Antiviral Approaches against Influenza Virus.Clinical microbiology reviews · 2023Review
- Type-I interferons in the immunopathogenesis and treatment of Coronavirus disease 2019.European journal of pharmacology · 2022Review
- Review
- Understanding Immune Responses to Viruses-Do Underlying Th1/Th2 Cell Biases Predict Outcome?Viruses · 2022Review
- Interferon-based agents for current and future viral respiratory infections: A scoping literature review of human studies.PLOS global public health · 2022Article
- A Game of Infection - Song of Respiratory Viruses and Interferons.Frontiers in cellular and infection microbiology · 2022Review
- Review
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Membrane (M) and Spike (S) Proteins Antagonize Host Type I Interferon Response.Frontiers in cellular and infection microbiology · 2021Article
- Towards a more effective strategy for COVID-19 prevention (Review).Experimental and therapeutic medicine · 2021Review
- Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic?Cytokine & growth factor reviews · 2020Review
- Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity?mSphere · 2020Article
- Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines.Molecular biomedicine · 2020Review
- The Role of Type I IFNs in Influenza: Antiviral Superheroes or Immunopathogenic Villains?Journal of innate immunity · 2020Review
- The dual role of innate immunity during influenza.Biomedical journal · 2019Review
- Antiviral potential of human IFN-α subtypes against influenza A H3N2 infection in human lung explants reveals subtype-specific activities.Emerging microbes & infections · 2019Article
- Advancements in Host-Based Interventions for Influenza Treatment.Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveInterferon alpha (IFNα) is a known antiviral agent. A double-blind, placebo-controlled clinical trial was conducted investigating the use of low-dose oral interferon alpha for preventing acute viral respiratory illnesses.
methodsTwo hundred healthy adults aged 18-75 years were enrolled and completed weekly health data questionnaires to monitor for symptoms and impact of respiratory illness. Serum samples were tested for antibodies against influenza and other common respiratory viruses.
resultsLow-dose oral IFNα prophylaxis did not reduce the incidence or impact of acute respiratory illness (ARI) or the impact of illness on daily activities. Post hoc analysis of participant subgroups, however, identified significant reductions in the incidence of ARI reported by males, those aged 50 years or more and those who received the 2009 seasonal influenza vaccine. Interferon alpha prophylaxis had a significant impact on the reporting of moderate-to-severe feverishness by the study population. Seropositive participants in the IFN group were more likely to report asymptomatic or mild symptoms compared with those in the placebo group who were more likely to report stronger symptoms.
conclusionsLow-dose oral IFNα prophylaxis was not effective in limiting the overall incidence of ARI in our study population. However, there was evidence that prophylaxis reduced the severity of symptoms and had a beneficial effect in some subpopulations, including those who received the 2009 seasonal trivalent influenza vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.